QUANTIB BV

Their core work

Quantib is a Rotterdam-based medical AI company that builds deep learning software for quantitative radiology — turning MRI scans into structured, measurable diagnostic data rather than relying on purely subjective radiologist interpretation. Their core capability is extracting imaging biomarkers from medical scans to support clinical decision-making, particularly in cancer and neurological disease. In practice, they develop and validate AI-driven tools that integrate radiology and pathology workflows, helping clinicians move toward standardized, reproducible diagnoses. They operate at the product end of medical AI: not just research algorithms, but clinically applicable diagnostic software.

What they specialise in

How they've shifted over time

Quantib entered H2020 in 2018 as a participant in B-Q MINDED, a brain MRI research project with no assigned keywords in the data — suggesting an early, exploratory collaboration role where they contributed technical capability but did not set the agenda. By 2020, their profile had sharpened dramatically: they took the coordinator role in ID-PROSTATE and brought a fully articulated keyword cluster covering prostate cancer, deep learning, radiomics, MRI, pathology, and quantitative imaging biomarkers. The direction is clear — from a broad medical imaging contributor to a focused, commercially-driven leader in AI-based prostate cancer diagnostics.

Quantib is moving from research participant toward product-owning coordinator, concentrating on prostate cancer as their primary clinical market — future collaborations are most likely to be applied, clinical-validation, or commercialization-oriented rather than foundational research.

How they like to work

Quantib has played both roles across just two projects: research partner in a large MSCA training network, then independent coordinator of a high-value SME Phase 2 project. This progression suggests a company that uses consortium participation strategically to build domain credibility before leading its own applied projects. With 13 unique partners across 5 countries spread over two projects, their network is modest in size but deliberately international, consistent with an SME expanding its clinical and academic validation footprint rather than a research hub maintaining long-term alliances.

Quantib has collaborated with 13 unique partners across 5 countries through two projects, suggesting a mix of academic medical centers, clinical partners, and possibly pathology or imaging technology firms. Their network spans Western Europe, reflecting the geography of both MRI neuroimaging research (B-Q MINDED) and clinical prostate cancer diagnostics (ID-PROSTATE).

What sets them apart

Quantib occupies a rare position as an SME that combines deep learning research capability with clinical application focus — they are not a university group publishing algorithms, nor a large vendor selling generic imaging software. Their ability to coordinate a €2.1M SME Phase 2 project in prostate cancer diagnostics signals that they have regulatory awareness, clinical partnerships, and a product pathway, which most pure AI research teams lack. For a consortium looking to connect AI methodology to real clinical workflow adoption, Quantib bridges that gap credibly.

Highlights from their portfolio

• ID-PROSTATE
  Quantib's largest project (€2.1M) and their only coordinator role — an SME Phase 2 award that validates their capacity to lead clinical AI development from MRI imaging through pathology integration to market-ready diagnostics.
• B-Q MINDED
  Participation in a Marie Skłodowska-Curie training network for brain disease MRI quantification shows Quantib's roots in fundamental quantitative imaging research and their value as a specialist industry partner in academic-led consortia.